Xealous Bio offers a microfluidic sperm selection platform that mimics natural rheotaxis to improve sperm quality for IVF. Their technology enhances blastocyst formation by selecting sperm with less DNA fragmentation and better separation rates compared to traditional methods. This leads to improved outcomes in assisted reproductive technology.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional sperm selection methods for in vitro fertilization (IVF) can damage sperm and may not effectively isolate the highest quality sperm, leading to lower fertilization rates and compromised embryo development. Current techniques often lack the ability to mimic the natural selection processes within the female reproductive tract.
Solution
Xealous Bio offers a microfluidic sperm selection platform that utilizes rheotaxis, mimicking the natural processes of the female reproductive tract, to isolate high-quality sperm for IVF. The platform's microfluidic chip guides sperm selection based on their ability to swim against a controlled fluid flow, isolating those with superior motility and reduced DNA fragmentation. By selecting sperm with enhanced characteristics, Xealous Bio's technology improves blastocyst formation rates and overall embryo quality. This approach leads to improved outcomes in assisted reproductive technology by ensuring that only the most viable sperm are used for fertilization.
Target Audience
The primary target audience includes IVF clinics, reproductive medicine centers, and research institutions seeking to improve sperm selection methods and enhance the success rates of assisted reproductive technologies.
Features
- Microfluidic chip design that mimics natural rheotaxis for sperm selection
- Flow rate control to select sperm based on motility and swimming speed
- Isolation of sperm with reduced DNA fragmentation compared to traditional methods
- Enhanced blastocyst formation rates demonstrated in bovine studies
- Improved sperm morphology and motility in selected samples
- Automated fertilization and ICSI capabilities (in progress)